Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - AB 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 24088.58 
• Atom Count: 1511 
• Residue Count: 218 
• Unique protein chains: 2

5DC4

CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL A

• DOI: 10.2210/pdb5DC4/pdb

• Classification: PROTEIN BINDING
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)


• Deposited: 2015-08-23 Released: 2016-03-02 
• Deposition Author(s): Wojcik, J.B., Koide, A., Koide, S.
• Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences; National Institutes of Health/National Cancer Institute 

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.48 Å
• R-Value Free: 0.190 
• R-Value Work: 0.144 

Literature

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface.

Wojcik, J., Lamontanara, A.J., Grabe, G., Koide, A., Akin, L., Gerig, B., Hantschel, O., Koide, S.

(2016) J.Biol.Chem. 291: 8836-8847

• PubMed: 26912659 
• DOI: 10.1074/jbc.M115.707901
• Primary Citation of Related Structures:  
  5DC9, 5DC0


• PubMed Abstract: 
  

Bcr-Abl is a constitutively active kinase that causes chronic myelogenous leukemia. We have shown that a tandem fusion of two designed binding proteins, termed monobodies, directed to the interaction interface between the Src homology 2 (SH2) and kinase domains and to the phosphotyrosine-binding site of the SH2 domain, respectively, inhibits the Bcr-Abl kinase activity. Because the latter monobody inhibits processive phosphorylation by Bcr-Abl and the SH2-kinase interface is occluded in the active kinase, it remained undetermined whether targeting the SH2-kinase interface alone was sufficient for Bcr-Abl inhibition. To address this question, we generated new, higher affinity monobodies with single nanomolar KD values targeting the kinase-binding surface of SH2. Structural and mutagenesis studies revealed the molecular underpinnings of the monobody-SH2 interactions. Importantly, the new monobodies inhibited Bcr-Abl kinase activity in vitro and in cells, and they potently induced cell death in chronic myelogenous leukemia cell lines. This work provides strong evidence for the SH2-kinase interface as a pharmacologically tractable site for allosteric inhibition of Bcr-Abl.

---

Organizational Affiliation: 

From the Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, Illinois 60637.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Tyrosine-protein kinase ABL1	A	123	Homo sapiens	Mutation(s): 0  Gene Names: ABL1 (ABL, JTK7) EC: 2.7.10.2
Find proteins for P00519 (Homo sapiens) Go to Gene View: ABL1 Go to UniProtKB:  P00519

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
AS25 monobody	B	95	Homo sapiens	Mutation(s): 0  Gene Names: FN1 (FN)
Find proteins for P02751 (Homo sapiens) Go to Gene View: FN1 Go to UniProtKB:  P02751

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
GOL	A	GLYCEROL GLYCERIN; PROPANE-1,2,3-TRIOL C3 H8 O3 PEDCQBHIVMGVHV-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.48 Å
• R-Value Free: 0.190 
• R-Value Work: 0.144 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 61.281	α = 90.00
b = 74.928	β = 90.00
c = 39.229	γ = 90.00

Software Package:

Software Name	Purpose
DENZO	data reduction
SCALEPACK	data scaling
REFMAC	refinement
PHASER	phasing
HKL-2000	data collection

Structure Validation

Entry History & Funding Information

Deposition Data

• Deposited Date: 2015-08-23 
• Released Date: 2016-03-02 
• Deposition Author(s): Wojcik, J.B., Koide, A., Koide, S.

---

Funding Organization	Location	Grant Number
National Institutes of Health/National Institute of General Medical Sciences	United States	R01-GM090324
National Institutes of Health/National Institute of General Medical Sciences	United States	T32GM07281
National Institutes of Health/National Cancer Institute	United States	P30CA014599

Revision History 

• Version 1.0: 2016-03-02
  Type: Initial release
• Version 1.1: 2016-03-09
  Type: Data collection
• Version 1.2: 2016-05-11
  Type: Database references
• Version 1.3: 2017-09-20
  Type: Author supporting evidence, Database references, Derived calculations